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a b s t r a c t
Transcatheter aortic valve replacement (TAVR) has rapidly emerged as the standard of care
for severe symptomatic aortic stenosis in patients whose comorbidities put them at
prohibitive risk for surgical aortic valve replacement (SAVR). Several trials have demon-
strated superior outcomes with TAVR compared to medical management alone. TAVR has
also shown favorable outcomes in patients at high risk for SAVR. TAVR can be associated
with signiﬁcant vascular complications, which adversely impact outcomes, and operators
should be cognizant of their early recognition and appropriate management. In this article,
we review the major vascular complications associated with TAVR, along with optimal
prevention and management strategies.
# 2015 Cardiological Society of India. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Since the ﬁrst reported human case,1 transcatheter aortic
valve replacement (TAVR) has rapidly emerged as a viable
strategy for treatment of subsets of patients with severe aortic
stenosis (AS). There is strong evidence that in patients deemed
‘‘inoperable’’ or ‘‘extreme risk’’ for conventional cardiac
surgery (surgical aortic valve replacement, SAVR), TAVR is
associated with signiﬁcant improvements in mortality, mor-
bidity, and quality of life compared to medical therapy alone.2,3
In patients at high risk for SAVR, transcatheter implantation
has demonstrated extremely favorable results.4 In the United
States, TAVR with the balloon-expandable Edwards Sapien* Corresponding author.
E-mail address: guptasa@ohsu.edu (S. Gupta).
http://dx.doi.org/10.1016/j.ihj.2015.11.024
0019-4832/# 2015 Cardiological Society of India. Published by Elsevier 
(http://creativecommons.org/licenses/by-nc-nd/4.0/).valve (Edwards Lifesciences Inc., Irvine, CA) and the self-
expanding Medtronic Core Valve system (Medtronic, Min-
neapolis, MN) are approved by the Federal Drugs Adminis-
tration (FDA) as acceptable treatment options for patients
with severe AS who cannot undergo surgery (inoperable).
More recently, the FDA has approved Medtronic CoreValve
Evolut systems (which use 14 F inline sheath-http://www.
mddionline.com/article/fda-approves-medtronic's-evolut-
r-tavr-06-24-15) and Sapien 3 valve systems (which uses an
expandable e-sheaths http://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm451678.htm). These
devices have already been available in other markets
including Europe. TAVR is also an acceptable alternative
for patients deemed to be at high risk for SAVR asB.V. This is an open access article under the CC BY-NC-ND license
Table 1 – Vascular access site and access related
complications.
Major vascular complications
Any aortic dissection, aortic rupture, annulus rupture, left ventricle
perforation, or new apical aneurysm/pseudoaneurysm OR
Access site or access-related vascular injury (dissection, stenosis,
perforation, rupture, arterio-venous ﬁstula, pseudoaneurysm,
hematoma, irreversible nerve injury, compartment syndrome,
percutaneous closure device failure) leading to death, life
threatening or major bleeding, visceral ischemia, or
neurological impairment OR
Distal embolization (noncerebral) from a vascular source
requiring surgery or resulting in amputation or irreversible
end-organ damage OR
The use of unplanned endovascular or surgical intervention
associated with death, major bleeding, visceral ischemia, or
neurological impairment OR
Any new ipsilateral lower extremity ischemia documented by
patient symptoms, physical exam, and/or decreased or absent
blood ﬂow on lower extremity angiogram OR
Surgery for access site-related nerve injury OR
Permanent access site-related nerve injury
Minor vascular complications
Access site or access-related vascular injury (dissection, stenosis,
perforation, rupture, arterio-venous ﬁstula, pseudoaneurysms,
hematomas, percutaneous closure device failure) not leading to
death, life-threatening or major bleeding, visceral ischemia, or
neurological impairment OR
Distal embolization treated with embolectomy and/or
thrombectomy and not resulting in amputation or irreversible
end-organ damage OR
Any unplanned endovascular stenting or unplanned surgical
intervention not meeting the criteria for a major vascular
complication OR
Vascular repair or the need for vascular repair (via surgery,
ultrasound-guided compression, transcatheter embolization, or
stent-graft)
Reproduced with permission.24
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trials have demonstrated similar beneﬁts in patients estimated
to be at moderate risk.9–11 Compared to initial TAVR procedures,
which were performed via an antegrade trans-septal approach,
the favored access method is via a transfemoral approach (TF-
TAVR). Increasingly, it is less common to access via a transapical
approach (TA-TAVR). TA-TAVR is an independent predictor of
adverse outcomes from TAVR, and when feasible, a transarterial
approach is preferred.12 Other access routes, such as axillary
artery, subclavian artery, carotid artery, transcaval, or direct
aortic access, are also utilized but constitute only a minority of
the cases.
TAVR is associated with several procedure-speciﬁc risks that
signiﬁcantly contribute to peri- and postprocedural, as well as
long-term morbidity and mortality. These include vascular
complications, embolic events (neurological complications,
such as cerebrovascular accidents), renal failure, paravalvular
leaks, and conduction system disturbances necessitating
permanent pacemaker (PPM) implantation. However, with the
possible exception of PPM with self-expanding prosthesis,
vascular complications are by far the most common6,13 and
generally manifest either periprocedurally or early in the
postprocedure period. Multiple studies have substantiated
higher mortality in patients with vascular complications.3,14–18
Increasingly, endovascular specialists are called on for diagnosis
and management of these complications. For successful out-
comes, these procedures require a cohesive well-functioning
multidisciplinary Heart Team. In this article, we aim to provide a
broad overview of vascular complications including their
incidence, risk factors, and diagnosis, along with optimal
prevention and management strategies.
2. Clinical relevance
TF-TAVR involves directing a crimped valve prosthesis
(balloon mounted or self-expanding) retrograde through the
aortic valve over a stiff guidewire positioned in the left
ventricular cavity. This requires placement of large-sized
sheaths via the femoral vessels. Patients require careful
assessment of the pelvic vasculature, usually with the help
of a preprocedure contrast-enhanced CT or pelvic angiography
to ensure suitability of the pelvic vessels to accommodate the
large sheaths. Despite this, vascular complications are
common and are major impediments to successful out-
comes.19 They are associated with increased mortality,
increased length of hospital stay, and diminished quality of
life.18,20–22 They also predispose to other complications, such
as renal failure, infection, and neuropathies. As TAVR under-
goes rapid and widespread adoption, members of the heart
team must be aware of these complications, recognize them
early, and initiate timely and appropriate management.
3. Incidence of vascular complications post-
TAVR
Assessing accurate incidence of vascular complications from
earlier trials is limited by initial lack of standard deﬁnitions
and reported rates have varied widely from 1.9% to30.7%.18,20,23 The risk increases with the size of the valve
delivery system. Valve Academic Research Consortium (VARC)
has established standard deﬁnitions for TAVR-related com-
plications (Table 1), grouping them into major and minor
complications.24,25
Using standard VARC deﬁnitions, the incidence of major
vascular complications varies between 10% and 20%.20,21,26 In a
large meta-analysis by Genereux et al. using VARC-1 deﬁni-
tions,13 the incidence of major vascular complications was
11.9% with major bleeding occurring in 15.6% of the patients.
Another study utilizing VARC deﬁnitions noted that major
vascular complications occurred in 17.3% and minor vascular
complications occurred in 10.2% of the patients.20 Earlier
studies have shown that the incidence of major vascular
complications is lower with Medtronic core valves compared
to earlier-generation Edwards Sapien valves, but more recent
literature with newer-generation Edwards Sapien devices
have shown the rate of major vascular complications to be
similar across the two-valve devices.27
4. Impact on clinical outcomes
The occurrence of vascular complications is strongly associ-
ated with worse overall clinical outcomes. These patients
Fig. 1 – Impact of vascular complications on 30-day
mortality. Mortality was consistently higher in those with
vascular complications [16.9% (red dotted line) in those
with and 6.6% (blue dotted) without].28
Reproduced with permission.
Fig. 2 – A comparison of mean hospital length of stay in
patients without (blue) and with (red) major vascular
complications.
Fig. 3 – Complication rates with increasing operator
experience (vascular complications, major bleeding, and
unplanned surgery declined as operators gained
experience).23
Reproduced with permission.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 7 2 4 – 7 3 1726typically have worse 30-day and 1-year mortality.14,15,20,23,28,29
The estimated 30-day mortality is 16.9% in those with major
vascular complications compared to 6.6% in those without
(Fig. 1).14,15,20,23,29 These patients also have signiﬁcantly more
hospital days adding to the total cost of the procedure (Fig. 2).
Thus, vascular complications are a major deterrent to
successful outcomes in patients undergoing TAVR.
5. Risk factors
Several risk factors (Table 2) are associated with an increased
risk of vascular complications. Center experience, sheath-to-
femoral artery ratio of >1.05, pelvic vessel calciﬁcation
(especially circumferential calciﬁcation), peripheral vascularTable 2 – Risk factors for vascular complications from
TAVR.
Female gender
Center and operator inexperience
Sheath to femoral arterial ratio of >1.05
Moderate to severe vascular calciﬁcation
Peripheral arterial disease
Sheath size > 19 F
External sheath diameter more than minimal arterial diameterdisease, female gender, and external sheath diameter more
than minimal arterial diameter are established as indepen-
dent predictors in multiple studies.18,20,23,28,30 The rate of
vascular complications decreases with increasing operator
experience (Fig. 3),23,31 use of smaller size sheaths, and better
patient selection.15,23,31 Systems using >19 F sheaths have
been associated with increased risk of major vascular
complications.21,32 The Medtronic Core Valve has been
associated with a lower risk of vascular complications
compared to the older-generation Edward Sapien devices that
required sheaths with an inner diameter of 22–24 F (outer
diameter 25–28 F).23 Similarly, the newer-generation lower
proﬁle Sapien XT valves (18 or 19 F delivery systems) and
Edward Sapien valve 3 systems (with even smaller delivery
systems) have a decreasing incidence of major vascular
complications compared to the ﬁrst-generation Edward Sapien
valves.32 A large multicenter registry from Europe showed
markedly improved vascular complication rates, 3.1% from all
access sites combined and 2.9% from the transfemoral access
site.33 Most patients were treated with either 18 F Edwards
Sapien XT or the Medtronic Core Valve. There was no
difference in the rate of vascular complications from Med-
tronic Core Valve versus Edwards Sapien XT valves (2.8% vs.
3.3%; p = 0.66). These results highlight the importance of
operator and center experience, as well as sheath size, toward
occurrence of vascular complications. With the recent approv-
al of Medtronic core valve Evolut systems, which use 14 F
sheath and Edward Sapien valve 3 systems, which use a 14 F
expandable sheath, the real-world incidence of vascular
complications is expected to decline.
6. Speciﬁc vascular complications
The common femoral artery is the more commonly used
access site during TAVR with 70% of the procedures being
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using this approach include aortic dissection, aortic rupture,
pelvic vessel dissection, pelvic vessel rupture, access site
hematoma, and pseudoaneurysm formation. When vascular
injury is suspected, general supportive measures, such as
volume resuscitation, should be promptly initiated to prevent
precipitous hemodynamic decline. The reason for a change in
patient's clinical status should be aggressively pursued as
conditions other than vascular complications, such as coro-
nary artery obstruction, paravalvular leaks, and acute valve
dysfunction, may present similarly. Once recognized, endo-
vascular treatment is the mainstay of managing vascular
complications.
7. Aortic dissection
Aortic dissection is a relatively rare but potentially deadly
complication from TAVR, with reported incidence between
0.6% and 1.9%.29,35 Depending on route of access (transfemoral,
transapical, subclavian, or direct aortic), any segment of the
aorta (from the ascending aorta to abdominal aorta) is a
potential site for iatrogenic injury.36
The signs and symptoms may not manifest until after the
procedure. At most centers, TAVR is performed under
concurrent transesophageal echocardiographic guidance
and it is routine to assess the ascending aorta post valve
deployment to exclude Stanford type A dissections. If
diagnosis is suspected peri-procedurally, angiography is
generally diagnostic. If unrecognized until the postproce-
dure period, patients may complain of sharp chest pain if
they develop Stanford type A or B dissection, or abdominal
pain if the dissection involves the abdominal aorta. With
extension into other vascular beds, there may be additional
symptoms, such as neurological compromise (from carotid
artery involvement), mesenteric ischemia (from involve-
ment of mesenteric arteries), or renal dysfunction. Patients
may also manifest differential blood pressure measured
between the two arms or the arms and legs. Postprocedure,
CT, transesophageal echocardiography, or MRI may be
utilized depending on institutional expertise and availability
for diagnosis.
The management of aortic dissection in the setting of
TAVR is the same as spontaneous aortic dissection, and
depends on the site of dissection and the presence of branch
vessel compromise. If the patients are hypertensive, aggres-
sive control of blood pressure with b-blockers (or nondihy-
dropyridine calcium channel blockers in patients with
contraindication to b-blockers) is required. Direct arterial
vasodilators, such as hydralazine, should be avoided. If the
patients are hypotensive, ﬂuids should be administered to
maintain a MAP of ≥70 mm of Hg. Urgent surgical consultation
should be obtained. Patients with Stanford type A aortic
dissection and those patients who are hypotensive without
alternative explanations should undergo surgical repair.
Hemodynamically stable patients with Stanford type B
dissection may be candidates for medical management or,
rarely, endovascular repair. Medical management involves
appropriate blood pressure and heart rate control with close
follow-up.8. Aortic rupture
Aortic rupture is a rare occurrence (<1%) but generally
catastrophic.37 Infrequently, the patient may present sub-
acutely due to an initial aortic injury that may gradually
enlarge in size leading to serious bleeding. Rupture can occur
from puncture of the aorta by the delivery catheter, especially
if the device is inadvertently advanced without a guidewire, or
if excessive force is applied when trying to advance around an
acute angulation in a tortuous aorta. The diagnosis requires a
high index of suspicion and should be considered in any
patient undergoing TAVR who develops hemodynamic com-
promise.
Aortic rupture leads to rapidly progressing hemorrhagic
shock with hypoperfusion of the extremities and vital organs.
The patients develop signs and symptoms of volume loss, such
as hypotension, tachycardia, and lactic acidosis. Depending on
the size and location of the tear, there may be gradual or
sudden decompensation of hemodynamics. In stable patients
with contained rupture, the diagnosis can be conﬁrmed by
angiography or CT angiography (CTA).
Aortic rupture is a life-threatening emergency. The
management options include surgical versus endovascular
repair with covered stent grafts and depend on the site of
injury. Despite appropriate interventions, mortality remains
high.
9. Pelvic vessel dissection
Pelvic vessel dissection is the most common vascular
complication in patients undergoing TAVR via the transfe-
moral route and has been reported to occur in about 6.5% of the
patients.18 The most frequent vessel dissected is the external
iliac artery. Injury typically occurs during initial placement of
the delivery sheath but is generally not apparent until the
sheath is withdrawn.
Typically, pelvic vessel dissections are recognized after
sheath removal, on routine angiography either retrograde
through the delivery sheath or more commonly antegrade
from an angiography catheter inserted from the contralateral
groin. Extensive dissections may compromise vascular ﬂow to
the lower extremity and predispose to rupture. Small dissec-
tions may be initially unrecognized but may lead to vascular
compromise in the postprocedure period, either from abrupt
closure due to thrombus formation or collection of signiﬁcant
amount of blood in the false lumen with a resultant
compression of the surrounding neurovascular structures.
Diagnosis can be conﬁrmed by either invasive angiography
(Fig. 4) or CTA or vascular Doppler.
The natural history of small nonﬂow-limiting retrograde
dissections is benign, and if the dissection is small with no
neurovascular compromise, then watchful waiting and close
monitoring is preferred to allow spontaneous healing. In
patients with vascular compromise or with extensive or
expanding dissections, intervention is generally warranted.
Endovascular repair is associated with good outcomes and
is the preferred treatment modality.32,38 Treatment is with
either angioplasty alone or with adjunctive stent placement if
Fig. 4 – Postprocedure invasive angiography showing
external iliac artery dissection with thrombus (green
arrow).
Fig. 6 – Postprocedure retrograde angiogram showing
contrast extravasation from right external iliac artery,
which is diagnostic of perforation and rupture (red arrow).
An occlusive balloon is noted proximal to the site of vessel
injury (green arrow).
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plasty involves prolonged balloon inﬂation with an appropri-
ately sized balloon that may be sufﬁcient to seal the dissection
ﬂap. If signiﬁcant compromise to ﬂow persists despite
prolonged balloon inﬂation, self-expanding stents are useful
(Fig. 5). If not technically feasible or unsuccessful, surgical
repair may be infrequently required. Patients should be
followed closely after repair and clinical exam and duplex
ultrasonography are helpful to ensure vascular healing and
patency.
10. Pelvic vessel rupture
Pelvic vessel rupture is a potentially fatal complication of
TAVR. Historically, it has been reported to occur in about 3–5%
of the patients and is associated with high mortality. With theFig. 5 – External iliac artery postdeployment of self-
expanding stent for management of arterial dissection
showing resolution of dissection and return of normal flow.
(Green arrow points to the site of previous dissection.)advent of low-proﬁle delivery systems, the incidence of pelvic
vessel rupture has declined. Pelvic vessel rupture typically
manifests after the sheath is withdrawn; as while the sheath is
present, it acts as seal for the tear.39 These patients can
decompensate very rapidly and exsanguinate unless prompt
intervention is undertaken.
Careful attention to hemodynamics at the time of sheath
removal is mandatory. Depending on the severity of
bleeding, patients may manifest immediate hemodynamic
instability, or in a delayed fashion several hours later.
Patients may develop transient hypotension associated with
return of circulation to an ischemic limb (due to large sheath
sizes, it is common for the limb to have very little blood ﬂow
while the delivery sheath is in place). Other causes of acute
hemodynamic compromise should be excluded. In most
centers, it is routine to perform pelvic angiography upon
sheath withdrawal (leaving the guidewire in place) with the
tip positioned in the common femoral artery, which may
show extravasation of the contrast material into extravas-
cular space in addition to localizing the site of rupture
(Fig. 6).
The immediate treatment involves re-advancing the
sheath and the dilator to the abdominal aorta that can serve
to tamponade the rupture site. This allows time for initiation
of supportive measures, such as rapid volume resuscitation
(normal saline, packed red cell transfusion), reversal of
periprocedural anticoagulation, and advancement of a proxi-
mal occlusion balloon, typically from the contralateral access
site. In some cases, the tear may seal-off after prolonged
balloon inﬂation and reversal of periprocedural anticoagula-
tion. Deﬁnitive therapy includes a covered stent that leads to
complete resolution in most cases.32 Rarely, if vascular
anatomy is unfavorable, injury at multiple sites is suspected,
or when endovascular treatment is unsuccessful, direct
vascular repair may be necessary.
Table 3 – Recommendations for assessment of access
route by CT before TAVI/TAVR.
CT imaging should be performed for vascular access assessment
(pelvic arteries and aorta) when not contraindicated
CT examinations should be performed with iodinated contrast
medium
Manual multiplanar reformation or semi-automated centerline
reconstruction should be used to achieve cross-sectional
visualization for measurement of vessel dimensions. From
these reconstructed images, the minimal luminal diameter
along the course of the vascular access should be determined
Qualitative assessment of vascular tortuosity should be
performed
Qualitative assessment of vascular calciﬁcation should be
performed
Consideration to varied thresholds of vessel size (sheath/femoral
artery ratio) should be contemplated, depending on the
presence and extent of vascular calciﬁcation
The left ventricle should be evaluated for the presence of
thrombus and, if a transapical access route is planned, for
geometry and position of the apex
Reproduced with permission.41
Table 4 – Recommendations for assessment of aorta.
The entire aorta should be imaged and evaluated, unless a
transapical access is planned
Severe elongation and kinking of the aorta, dissection, and
obstructions caused by thrombus or other material should be
reported
Reproduced with permission.41
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pseudoaneurysm
Access site hematomas are common, occurring either imme-
diately or within several hours to days of TAVR. The incidence
is declining due to increasing operator experience, meticulous
access technique, and decreasing sheath sizes. Generally, they
are benign, with spontaneous resolution over time. However,
they increase the risk of secondary infection and rapidly
expanding hematomas may be associated with signiﬁcant
comorbidity from compression of the surrounding structures
and blood loss.
The patients generally complain of persistent pain and
swelling at the access site and diagnosis is established based
on the clinical exam. Duplex ultrasound can be helpful to
evaluate the size (especially in obese patients) and exclude
femoral pseudoaneurysms.
In most instances, hematomas can be managed conserva-
tively with close monitoring as long as there is no active
bleeding from the access site. If active bleeding is present, this
should be managed with manual digital compression. Reversal
of anticoagulation (typically unfractionated heparin is used
periprocedurally) should be considered. Once active bleeding
is controlled, hematomas resorb over a period of few days to
weeks. Supportive measures, such as pain control, generally
sufﬁce. Care must be taken to prevent secondary infection.
Surgical evacuation may be considered in large hematomas
and hematomas that are associated with compressive
symptoms, such as painful neuropathy. Pseudoaneurysms
are managed in most cases with ultrasound-guided compres-
sion or direct thrombin injection. Surgical repair may be
needed if these therapies are unsuccessful.
12. Prevention
As vascular complications are such a major determinant of
ultimate outcome from TAVR, all possible steps must be taken
to prevent them. Great attention should be paid toward a
meticulous access technique to avoid any possible vessel
injury. Knowledge of the patient's vascular anatomy and
appropriate patient selection is critical and preprocedural CTA
plays a major role in procedural planning.
13. Role of CTA in preventing vascular
complications
Preprocedure CTA is now the standard of care and is used
routinely in planning for patients being considered for TAVR.7
CTA provides a road map of the aorta and the pelvic vessel
anatomy to the operators.40 A consensus statement by the
Society of Cardiovascular CT outlines the recommendations
for assessment of access site and aorta in patients for whom
TAVR is being planned (Tables 3 and 4).41 The image
acquisition is typically gated and extends from the arch of
the aorta to below the femoral head.
CT allows for measurement of the aortic annulus and
appropriate sizing of the valve, thereby reducing the risk ofrupture of the aortic annulus or undersizing of the valve that
predisposes to paravalvular leaks. Aortic dissection, aneur-
ysms, calciﬁcations, and atheroma are easily recognized on
CTA. Similarly, pelvic vessel diameters are measured by CT
with careful attention to assessment of tortuosity, calciﬁcation
(specially horseshoe or circumferential calciﬁcation), and
kinking. This information is vital to guide the choice of access
route and appropriate sheath and device selection. Most TAVR
centers have well-established protocols for pre-TAVR assess-
ment, typically interpreted by a radiologist with close
familiarity with the device and in-depth understanding of
the procedural components. At our institution, a dedicated
chest radiologist and interventional radiologist are members
of the Heart Team and regularly participate in adjudicating the
suitability of patients for a transcatheter procedure in a
multidisciplinary valve listing conference.
14. Future directions
As larger size catheters are associated with an increased risk of
complications, there is strong impetus toward development of
devices that can be delivered through smaller sheaths.
Technological advances continue to allow development of
lower proﬁle devices. Sheath technology has also undergone
signiﬁcant enhancements. Expandable sheaths (Edwards
eSheath) allow for transient sheath expansion during valve
delivery. Immediately after the Transcatheter Heart valve
passes through the sheath, the sheath is designed to return to
a low-proﬁle diameter. This reduces the time the access vessel
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The Edward Sapien 3 system and Medtronic's CoreValve Evout
R systems, approved in the US in 2015, are steps in this
direction. Both catheter systems have sheath proﬁles <18 F
and are expected to signiﬁcantly reduce vascular complica-
tions from TAVR, leading to more optimal patient outcomes.
15. Summary
Since ﬁrst performed in 2002 via trans-septal puncture, TAVR
has undergone rapid evolution. The indications for this
procedure are expanding and there are several possible access
sites (transfemoral, transapical, transaxillary, subclavian, or
direct aortic). CTA plays a key role in preprocedure planning
and the appropriate access site is chosen based on patient's
anatomy, risk factors, and available institutional expertise.
Regardless, meticulous vascular access is critical. Vascular
injury is amongst the commonest complications of this life-
saving procedure. Prompt recognition and early treatment are
vital to prevent signiﬁcant morbidity and mortality.
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